(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Competency based placement focussed Education | Training | Research | Consultancy
Tandem Diabetes Care has received clearance from the US Food and Drug Administration (FDA) for a tubeless version of its Mobi automated insulin delivery system, introducing a new option for people managing diabetes. The updated system is designed to allow insulin delivery without conventional tubing and can be worn for up to seven days using a new infusion set.
The development builds on Tandem's existing Mobi insulin pump, which uses Control-IQ+ technology to support automated insulin delivery. The newly cleared cartridge and infusion set allow the existing pump to be used in a tubeless configuration, giving users the choice between tubed and tubeless delivery depending on their preferences and needs.
The tubeless design is expected to provide greater flexibility during everyday activities while reducing the frequency of infusion site changes. The system is intended to make insulin therapy more convenient without compromising the automated delivery technology already available in the Mobi platform.
Tandem plans to introduce the new tubeless accessories commercially in the United States during the first half of 2027. Patients who already own an eligible Mobi pump will not need to purchase a new pump to use the updated configuration, as the new cartridge and infusion set are designed to work with existing devices.
The clearance represents another development in wearable diabetes technology, as medical device manufacturers continue to focus on improving treatment convenience, flexibility and patient experience through advancements in insulin delivery systems.
16-11-2026